Bedrocan has entered into a partnership with Medios AG, a European provider of specialised medicines, with its headquarters in Berlin. Under this agreement, Medios AG becomes Bedrocan's chosen distribution partner of its medicinal cannabis products for Germany, with plans to gradually expand the partnership to Austria, Belgium, Italy and Spain.
Medios will distribute medicinal cannabis produced at Bedrocan's Danish facility to pharmacies and wholesalers throughout Germany. To ensure a seamless transition, Medios will leverage the expertise and network of Cannaflos, which has been distributing Bedrocan's products in Germany since 2020. Medicinal cannabis produced by Bedrocan in the Netherlands will continue to be exported by the Office for Medicinal Cannabis for the time being.
Extensive reach and pharmaceutical alignment
The selection of Medios AG was driven by its extensive reach and knowledge of individualised medicine. Bedrocan's CEO Jaap Erkelens explained: "From the very beginning, our cannabis has been exclusively intended for patients or drug developers. This pharmaceutical approach has allowed us to connect with a reputable pharmaceutical distributor like Medios. We are therefore thrilled to have found a reliable and solid distribution partner to get our products to German patients." Medios distributes medicines throughout Germany and produces specialised medications and patient-specific therapies.
One-stop-shop for German pharmacists
The collaboration simplifies the procurement process for pharmacists, who previously navigated a fragmented market of dozens of smaller distributors to secure Bedrocan's products. This often led to supply inconsistencies and administrative burdens. Erkelens: "With this collaboration, we are introducing a one-stop-shop for pharmacists to place their orders. They no longer have to visit dozens of distributors in their search for Bedrocan's cannabis.
For more information:
Bedrocan
e: [email protected]
www.bedrocan.com
